Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis

Abstract MicroRNAs (miRNAs) are now known to play important roles in the regulation of gene expression for developmental timing, cell proliferation and apoptosis. Therefore, it is likely that they also modulate sensitivity and resistance to anti-cancer drugs. To better understand the molecular mecha...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2010-06, Vol.46 (9), p.1692-1702
Main Authors: Guo, Linlang, Liu, Yongguang, Bai, Yifeng, Sun, Yanqin, Xiao, Faman, Guo, Ying
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Cell Cycle - genetics
Cisplatin - therapeutic use
DNA, Complementary - metabolism
Doxorubicin - therapeutic use
Drug resistance
Drug Resistance, Multiple - genetics
Drug Resistance, Neoplasm - genetics
Etoposide - therapeutic use
Expression profile
Gene Expression Profiling - methods
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Medical sciences
Microarray Analysis - methods
MicroRNAs - metabolism
Pharmacology. Drug treatments
Reverse Transcriptase Polymerase Chain Reaction
RNA, Neoplasm - metabolism
Small cell lung cancer
Small Cell Lung Carcinoma - drug therapy
Small Cell Lung Carcinoma - genetics
Transfection
Tumor Cells, Cultured
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract MicroRNAs (miRNAs) are now known to play important roles in the regulation of gene expression for developmental timing, cell proliferation and apoptosis. Therefore, it is likely that they also modulate sensitivity and resistance to anti-cancer drugs. To better understand the molecular mechanisms of multidrug resistance in SCLC and identify novel molecular markers, we evaluated the expression of 856 miRNAs and ∼22,000 genes using miRNA microarray and cDNA microarray in cellular models of SCLC which were widely used as sensitive (NCI-H69) and resistant cell lines (NCI-H69AR) to chemotherapy. We also analysed the correlations between miRNA and mRNA expression patterns. Further studies were tested to determine whether the differentially expressed miRNAs were involved in multidrug resistance in SCLC. Our results showed that 61 miRNAs are presented significantly (>3-fold) including up-regulation of 24 miRNAs and down-regulation of 37 miRNAs. Among these miRNAs, 48 of 61 differentially expressed miRNAs were firstly reported to be closely associated with drug resistance and 37.7% (24/61) of miRNA genes were organised as 10 clusters in total 61 significantly expressed miRNAs. We also found that only 27 of 69 miRNAs were significantly correlated with 604 of 21,522 70 mRNA transcripts by MAS database. The sensitivity to anti-cancer drugs Cisplatin, Etoposide and Doxorubicin greatly increased or reduced following transfection of the drug-resistant H69AR cells with the mimics or antagomirs of miR-134, miR-379 and miR-495, respectively. miR-134 increases the cell survival by inducing G1 arrest in H69AR cells. MRP1/ABCC1 is negatively regulated by miR-134 and down-regulation of MRP1/ABCC1 at the protein level largely correlates with elevated levels of miR-134 in H69AR cells. Our results support for the first time a substantial role for miRNAs in multidrug resistance in SCLC. miR-134 could be a causal factor of the down-regulation of MRP1/ABCC1 in H69AR cells. These findings provide valuable information for potential utility of these miRNAs as specific diagnostic biomarkers and novel therapeutic approaches for drug resistance of SCLC.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2010.02.043